Publications
- Ocrelizumab in the treatment of multiple sclerosis - view of a neurologist and immunologist2018 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later2016 | First Faculty of Medicine
- Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party2015 | First Faculty of Medicine
- Timely treatment of multiple sclerosis: practical experience2015 | First Faculty of Medicine
- Interferon beta in the current treatment of multiple sclerosis2013 | First Faculty of Medicine
- High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience2010 | First Faculty of Medicine, Third Faculty of Medicine
- Autologous Hematopoietic Stem Cells Transplantation and its Current Role in Multiple Sclerosis Treatment2009 | First Faculty of Medicine, Third Faculty of Medicine
- A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking2009 | First Faculty of Medicine
- Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis2023 | First Faculty of Medicine, Third Faculty of Medicine
- To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection2022 | First Faculty of Medicine
Loading network view...
